drugset / Trial / NCT01783821

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

NCT01783821

RandomizedParallel-groupDouble-blindPrevention

Summary

This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome (ARDS). The FDA has approved many uses for budesonide and formoterol, including asthma and chronic obstructive pulmonary disease (COPD), but the use of these two drugs is experimental for ARDS.

Timeline

Start
2013-07
Primary completion
2015-07
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 0.5 mg Inhaled
Subject Formoterol Other / unclassified 20 ug Inhaled